In CAIRO2 (capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer) and PACCE (panitumumab advanced colorectal cancer evaluation study) trials, the addition of anti-EGFR antibody to a combination of chemotherapy and bevacizumab significantly reduced the PFS [67, 68]. Here, EGFR is linked to colorectal cancer.